Citation Impact
Citing Papers
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
2004
Actos Now for the prevention of diabetes (ACT NOW) study
2009
Glitazones and the management of insulin resistance: what they do and how might they be used
2004
Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System
2004
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Inflammation and metabolic disorders
2006 StandoutNature
Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
2005
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
2011
Acute effects of gastric bypass versus gastric restrictive surgery on β-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes
2009
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
2009 Standout
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
2013
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
2013
Gestational diabetes mellitus
2005 Standout
Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials
2003
The metabolic syndrome
2010 Standout
Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications
2007
Bariatric Surgery
2004 Standout
Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation
2006 Standout
Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
2004 Standout
Preservation of β-Cell Function: The Key to Diabetes Prevention
2011
β-Cell function in type 2 diabetes
2014
Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
2017 Standout
Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view
2003
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
2007 Standout
Metabolic Changes in Pregnancy
2007
The replication of β cells in normal physiology, in disease and for therapy
2007
Inflammation and insulin resistance
2006 Standout
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
2007 StandoutNature
Obesity
2005 Standout
Host Remodeling of the Gut Microbiome and Metabolic Changes during Pregnancy
2012 Standout
Activation of Peroxisome Proliferator-Activated Receptor-γ by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3′-Kinase-Dependent Pathway
2005
The metabolic syndrome
2005 Standout
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
2006 Standout
Non-alcoholic fatty liver disease
2021 Standout
Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease
2010 Standout
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)
2006
Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study
2012
Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance
2004
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Type 2 diabetes
2017 Standout
Peroxisome proliferator–activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study
2007
Short Neuropeptide F Is a Sleep-Promoting Inhibitory Modulator
2013 StandoutNobel
Dysfunctional fat cells, lipotoxicity and type 2 diabetes
2004
Detecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls
2004
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
2012 Standout
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
Prevalence of Diabetes among Men and Women in China
2010 Standout
Type 1 diabetes
2013 Standout
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
2004
Disordered Lipid Metabolism and the Pathogenesis of Insulin Resistance
2007
Polycystic Ovary Syndrome
2005 Standout
Thiazolidinediones improve β-cell function in type 2 diabetic patients
2006
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
Metabolic syndrome after a pregnancy complicated by gestational diabetes
2008
Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes
2004
Associations between Sleep Loss and Increased Risk of Obesity and Diabetes
2008
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
2010
Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions
2008
Regression From Prediabetes to Normal Glucose Regulation Is Associated With Reduction in Cardiovascular Risk: Results From the Diabetes Prevention Program Outcomes Study
2014
Progress with thiazolidinediones in the management of type 2 diabetes mellitus
2004
The metabolic syndrome—a new worldwide definition
2005 Standout
Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome
2003
Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2)
2009
Polycystic ovary syndrome
1997
Contributions of -Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose
2006
Risk of development of diabetes mellitus after diagnosis of gestational diabetes
2008
Type 2 diabetes mellitus
2015 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
2008 Standout
Islet cell failure in type 2 diabetes
2006
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance
2009
Prevalence of type 2 diabetes among women with a previous history of gestational diabetes mellitus
2008
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
2006
Prediabetes: a high-risk state for diabetes development
2012 Standout
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
2016 StandoutNobel
GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress
2006
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
2003 Standout
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
2004
Restoration of Euglycemia and Normal Acute Insulin Response to Glucose in Obese Subjects With Type 2 Diabetes Following Bariatric Surgery
2003
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Prevention of type 2 diabetes; a systematic review and meta‐analysis of different intervention strategies
2014
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial
2014
Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose
2006
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial
2007
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
2013
Pioglitazone Reduces Islet Triglyceride Content and Restores Impaired Glucose-Stimulated Insulin Secretion in Heterozygous Peroxisome Proliferator–Activated Receptor-γ–Deficient Mice on a High-Fat Diet
2004
American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome
2003
The Metabolic Syndrome in Overweight Hispanic Youth and the Role of Insulin Sensitivity
2004
American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome
2003
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes
2010
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
2004
Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited
2004
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
2011
The Prevalence of the Metabolic Syndrome in a Danish Population of Women with Previous Gestational Diabetes Mellitus Is Three-Fold Higher than in the General Population
2005
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
2016
Changes in Insulin Secretion and Insulin Sensitivity in Relation to the Glycemic Outcomes in Subjects With Impaired Glucose Tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1)
2009
The Metabolic Syndrome as Predictor of Type 2 Diabetes
2003
Identifying Individuals at High Risk for Diabetes
2005
Nowy rok, stare problemy, ale i nowe możliwości
2014 Standout
Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes
2003
The molecular mechanisms of pancreatic β-cell glucotoxicity: Recent findings and future research directions
2012
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
2013
Prevention of Diabetes With Pioglitazone in ACT NOW
2013
Minimal Model-Based Insulin Sensitivity Has Greater Heritability and a Different Genetic Basis Than Homeostasis Model Assessment or Fasting Insulin
2003
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
2007
The Metabolic Syndrome
2008 Standout
Harmonizing the Metabolic Syndrome
2009 Standout
Minireview: Adiposity, Inflammation, and Atherogenesis
2003
Impact of Differences in Fasting Glucose and Glucose Tolerance on the Hyperbolic Relationship Between Insulin Sensitivity and Insulin Responses
2006
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
2003 Standout
Impaired Fasting Glucose and Impaired Glucose Tolerance
2007
β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy
2012
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
2006
Works of César Ochoa being referenced
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes
2007
Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women
2002
Effect of Pioglitazone on Pancreatic β-Cell Function and Diabetes Risk in Hispanic Women With Prior Gestational Diabetes
2006
Effect of Thiazolidinedione Treatment on Progression of Subclinical Atherosclerosis in Premenopausal Women at High Risk for Type 2 Diabetes
2005
Pharmacological Treatment of Insulin Resistance at Two Different Stages in the Evolution of Type 2 Diabetes: Impact on Glucose Tolerance and β-Cell Function
2004